TAG:
dna sequence
Whole Genome Sequencing Is Poised for Clinical Use
CEO SUMMARY: Pathologists and clinical lab managers interested in following the advances in use of whole human genome sequencing for clinical purposes should follow the money. Within weeks of obtaining FDA clearance for its MiSeqDx system and reagents, Illumina had inked major agreements …
Exome Sequencing Next “Big Thing” for Diagnosis
CEO SUMMARY: For disease diagnostics, exome sequencing is not yet routine, but geneticists are getting close. Using this technology, researchers read those parts of the human genome where about 85% of disease-causing mutations reside. By looking only at the regions that encode proteins—…
GHSU Graduates Med Techs Using Distance Training
CEO SUMMARY: Many clinical labs experiencing a shortage of trained medical laboratory scientists (MLS) in their city continue to overlook how the use of distance training programs could help them attract and retain top-performers. Leaders of the clinical laboratory scientist (CLS…
Whole Genome Sequencing: Is It Ready for Prime Time?
CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagn…
CYP450 Plays Major Role In Drug Metabolization
CEO SUMMARY: Each year, over 100 million new prescriptions are written for two classes of drugs with metabolic pathways affected by genetic variations in cytochrome P450. There are strong clinical arguments in favor of testing individuals for these genetic mutations to determine whether t…
“January 28, 2002 Intelligence: Late Breaking Lab News”
It may be a sign of change in how at least one national managed care company is willing to contract for laboratory services. During the last four weeks, UnitedHealthcare signed agreements with Dynacare, Inc. and Bio-Reference Laboratories, Inc. (BRLI). Dynacare operates labs in 21 st…
Beckman Coulter’s Strategy Reflects Consolidation Trends
CEO SUMMARY: Rapid changes to the clinical laboratory industry had equally profound impact upon the major diagnostic companies. At Beckman Coulter, Inc., market forces triggered a decade of acquisitions and internal consolidation.The company looks very different today than it did ten year…
CURRENT ISSUE
Volume XXXI, No. 5 – April 8, 2024
The fragmentation of consumer markets is reflected in clinical lab services, and The Dark Report examines this trend and how it will impact labs in the coming years. Also, The Dark Report notes that the FDA has issued a controversial memo to reclassify many high-risk IVD assays.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.